Effect of arginine vasopressin on the behavioral activity in the behavior despair depression rat model

Neuropeptides

Volumn 46, Issue 3, 2012, Pages 141-149

  Yang, Jun ^a   Pan, Yan Juan ^a   Yin, Zhi Kui ^a   Hai, Guang Fan ^a   Lu, Lu ^a   Zhao, Ying ^a   Wang, Da Xin ^b   Wang, Huan ^c   Wang, Gen ^c  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b YANGZHOU UNIVERSITY   (China)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Arginine vasopressin; Behavior despair; Brain; Depression; Periphery; V 1 receptor; V 2 receptor

Indexed keywords

ARGIPRESSIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; EXPERIMENT; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; HOPELESSNESS; IMMOBILIZATION; MALE; NEUROHYPOPHYSIS; NONHUMAN; PARAVENTRICULAR THALAMIC NUCLEUS; POSITIVE FEEDBACK; PRIORITY JOURNAL; RAT; SPINAL CORD; SUPRAOPTIC NUCLEUS; TAIL SUSPENSION TEST;

ANIMALS; ARGININE VASOPRESSIN; BEHAVIOR, ANIMAL; DEPRESSION; HELPLESSNESS, LEARNED; HINDLIMB SUSPENSION; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; MALE; PITUITARY GLAND; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; SPINAL CORD; SWIMMING;

ANIMALIA; RATTUS;

EID: 84860653142     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2012.03.003     Document Type: Article

References (99)

1. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol. 1994, 15:321-350.
2. Aguilera G., Rabadan-Diehl C. Regulation of vasopressin V1b receptors in the anterior pituitary gland of the rat. Exp. Physiol. 2000, 85:19S-26S.
3. Aguilera G., Pham Q., Rabadan-Diehl C. Regulation of pituitary vasopressin receptors during chronic stress: relationship to corticotroph responsiveness. J. Neuroendocrinol. 1994, 6:299-304.
4. Albers H.E., Bamshad M. Role of vasopressin and oxytocin in the control of social behavior in Syrian hamsters (Mesocricetus auratus). Prog. Brain Res. 1998, 119:395-407.
5. Albers H.E., Hennessey A.C., Whitman D.C. Vasopressin and the regulation of hamster social behavior. Ann. N. Y. Acad. Sci. 1992, 652:227-242.
6. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol. 1993, 14:76-122.
7. Antunes J.L., Zimmerman E.A. The hypothalamic magnocellular system of the rhesus monkey: an immunocytochemical study. J. Comp. Neurol. 1978, 181:539-565.
8. Bartolomeos K., Brown D., Butchart A., Harvey A., Meddings D., Sminkey L. Third Milestones of a Global Campaign for Violence Prevention Report 2007, WHO Library Cataloguing-In-Publication Data, World Health Organization, Geneva.
9. Bester-Meredith J.K., Marler C.A. Vasopressin and aggression in cross-fostered California mice (Peromyscus californicus) and white-footed mice (Peromyscus leucopus). Horm. Behav. 2001, 40:51-64.
10. Birnbaumer M. Vasopressin receptors. Trends Endocrinol. Metab. 2000, 11:406-410.
11. Blanchard R.J., Griebel G., Farrokhi C., Markham C., Yang M., Blanchard D.C. AVP V(1b) selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacol. Biochem. Behav. 2005, 80:189-194.
12. Boakes R.J., Ednie J.M., Edwardson J.A., Keith A.B., Sahgal A., Wright C. Abnormal behavioural changes associated with vasopressin-induced barrel rotations. Brain Res. 1985, 326:65-70.
13. Borsini F., Volterra G., Meli A. Does the behavioral "despair" test measure "despair" ?. Physiol. Behav. 1986, 38:385-386.
14. Bunck M., Czibere L., Horvath C., Graf C., Frank E., Kessler M.S., Murgatroyd C., Müller-Myhsok B., Gonik M., Weber P., Pütz B., Muigg P., Panhuysen M., Singewald N., Bettecken T., Deussing J.M., Holsboer F., Spengler D., Landgraf R. A hypomorphic vasopressin allele prevents anxiety-related behavior. PLoS One 2009, 4:e5129.
15. Caldwell H.K., Albers H.E. Effect of photoperiod on vasopressin-induced aggression in Syrian hamsters. Horm. Behav. 2004, 46:444-449.
16. Caldwell H.K., Lee H.J., Macbeth A.H., Young W.S. Vasopressin: behavioral roles of an "original" neuropeptide. Prog. Neurobiol. 2008, 84:1-24.
17. Caldwell H.K., Stewart J., Wiedholz L.M., Millstein R.A., Iacangelo A., Holmes A., Young W.S., Wersinger S.R. The acute intoxicating effects of ethanol are not dependent on the vasopressin 1a or 1b receptors. Neuropeptides 2006, 40:325-337.
18. Caldwell H.K., Young W.S. Persistence of reduced aggression in vasopressin 1b receptor knockout mice on a more "wild" background. Physiol. Behav. 2009, 97:131-134.
19. Chowdrey H.S., Larsen P.J., Harbuz M.S., Jessop D.S., Aguilera G., Eckland D.J., Lightman S.L. Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Br. J. Pharmacol. 1995, 116:2417-2424.
20. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29:571-625.
21. Everts H.G.J., de Ruiter A.J.H., Koolhaas J.M. Differential lateral septal vasopressin in wild-type rats: correlation with aggression. Horm. Behav. 1997, 31:136-144.
22. Ferris C.F., Lu S.F., Messenger T., Guillon C.D., Heindel N., Miller M., Koppel G., Robert B.F., Simon N.G. Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol. Biochem. Behav. 2006, 83:169-174.
23. Ferris C.F., Melloni R.H., Koppel G., Perry K.W., Fuller R.W., Delville Y. Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters. J. Neurosci. 1997, 17:4331-4340.
24. Ferris C.F., Potegal M. Vasopressin receptor blockade in the anterior hypothalamus suppresses aggression in hamsters. Physiol. Behav. 1988, 44:235-239.
25. Gillies G.E., Linton E.A., Lowry P.J. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 1982, 299:355-357.
26. Gispen-de Wied C.C., Westenberg H.G., Koppeschaar H.P., Thijssen J.H., van Ree J.M. Stimulation of the pituitary-adrenal axis with a low dose [Arg8]-vasopressin in depressed patients and healthy subjects. Eur. Neuropsychopharmacol. 1992, 2:411-419.
27. de Goeij D.C., Kvetnansky R., Whitnall M.H., Jezova D., Berkenbosch F., Tilders F.J. Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats. Neuroendocrinology 1991, 53:150-159.
28. de Goeij D.C., Jezova D., Tilders F.J. Repeated stress enhances vasopressin synthesis in corticotropin releasing factor neurons in the paraventricular nucleus. Brain Res. 1992, 577:165-168.
29. Grazzini E., Boccara G., Joubert D., Trueba M., Durroux T., Guillon G., Gallo-Payet N., Chouinard L., Payet M.D., Serradeil Le, Gal C. Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Adv. Exp. Med. Biol. 1998, 449:325-334.
30. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.P., Soubrie P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. PNAS 2002, 99:6370-6375.
31. Grippo A.J., Wu K.D., Hassan I., Carter C.S. Social isolation in prairie voles induces behaviors relevant to negative affect: toward the development of a rodent modent model focused on co-occurring depression and anxiety. Depress. Anxiety 2008, 25:E17-E26.
32. Guillon G., Derick S., Pena A., Cheng L.L., Stoev S., Seyer R., Morgat J.L., Barberis C., Gal C.S., Wagnon J., Manning M. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations. J. Neuroendocrinol. 2004, 16:356-361.
33. Hamilton R.D., Foss A.J., Leach L. Establishment of a human in vitro model of the outer blood-retinal barrier. J. Anat. 2007, 211:707-716.
34. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
35. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J. Affect. Disord. 2001, 62:77-91.
36. Iijima M., Chaki S. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog. Neuro-Psychoph. 2007, 31:622-627.
37. Jard S., Barberis C., Audigier S., Tribollet E. Neurohypophyseal hormone receptor systems in brain and periphery. Prog. Brain Res. 1987, 72:173-187.
38. Jochum T., Boettger M.K., Wigger A., Beiderbeck D., Neumann I.D., Landgraf R., Sauer H., Bar K.J. Decreased sensitivity to thermal pain in rats bred for high anxiety-related behaviour is attenuated by citalopram or diazepam treatment. Behav. Brain Res. 2007, 183:18-24.
39. Kasting N.W., Veale W.L., Cooper K.E. Convulsive and hypothermic effects of vasopressin in the brain of the rat. Can. J. Physiol. Pharmacol. 1980, 58:316-319.
40. Keverne E.B., Curley J.P. Vasopressin, oxytocin and social behaviour. Curr. Opin. Neurobiol. 2004, 14:777-783.
41. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. 2005, 6:463-475.
42. Landgraf R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol. Disord. Drug Targets 2006, 5:167-179.
43. Landgraf R., Kessler M.S., Bunck M., Murgatroyd C., Spengler D., Zimbelmann M., Nussbaumer M., Czibere L., Turck C.W., Singewald N., Rujescu D., Frank E. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci. Biobehav. Rev. 2007, 31:89-102.
44. Landgraf R., Neumann I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol. 2004, 25:150-176.
45. Landgraf R., Wigger A. High vs low anxiety-related behavior rats: an animal model of extremes in trait anxiety. Behav. Genet. 2002, 32:301-314.
46. Legros J.J., Ansseau M. Vasopressin-neurophysin and bipolar depression. Biol. Psychiatry 1986, 21:1212-1216.
47. Litvin Y., Murakami G., Pfaff D.W. Effects of chronic social defeat on behavioral and neural correlates of sociality: vasopressin, oxytocin and the vasopressinergic V1b receptor. Physiol. Behav. 2001, 103:393-403.
48. Liu Z., Lin B.C., Song C.Y., Wang C.H., Zhu Y.X. Preparation for anti-arginine vasopressin serum and its application. Acta Zool. Sin. 1987, 33:303-306.
49. Lolait S.J., O'Carroll A.M., Mahan L.C., Felder C.C., Button D.C., Young W.S., Mezey E., Brownstein M.J. Extrapituitary expression of the rat V1b vasopressin receptor gene. PNAS 1995, 92:6783-6787.
50. van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17:284-292.
51. van Londen L., Kerkhof G.A., van den B.F., Goekoop J.G., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., Wiegant V.M., De W.D. Plasma arginine vasopressin and motor activity in major depression. Biol. Psychiatry 1998, 43:196-204.
52. van Londen L., Goekoop J.G., Kerkhof G.A., Zwinderman K.H., Wiegant V.M., De W.D. Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression. Eur. Neuropsychopharmacol. 2001, 11:7-14.
53. Ma X.M., Levy A., Lightman S.L. Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. Endocrinology 1997, 138:4351-4357.
54. Ma X.M., Levy A., Lightman S.L. Rapid changes of heteronuclear RNA for arginine vasopressin but not for corticotropin releasing hormone in response to acute corticosterone administration. J. Neuroendocrinol. 1997, 9:723-728.
55. Ma X.M., Lightman S.L. The arginine vasopressin and corticotrophin-releasing hormone gene transcription responses to varied frequencies of repeated stress in rats. J. Physiol. 1998, 510:605-614.
56. Makino S., Smith M.A., Gold P.W. Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levels. Endocrinology 1995, 136:3299-3309.
57. McEwen B.B. The role of vasopressin and oxytocin in memory processing 2004, vol. 50. Elsevier Science, Amsterdam.
58. Mello A.A., Mello M.F., Carpenter L.L., Price L.H. Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. Rev. Bras. Psiquiatr. 2003, 25:231-238.
59. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Bedard T., Anisman H. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol. Psychiatry 2006, 59:594-602.
60. Michael R.P., Gibbson J.L. Interrelationships between the endocrine system and neuropsychiatry. Intern. Rev. Neurobiol. 1963, 5:243-302.
61. Mlynarik M., Zelena D., Bagdy G., Makara G.B., Jezova D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm. Behav. 2007, 51:395-405.
62. Morel A., Lolait S.J., Brownstein M.J. Molecular cloning and expression of rat V1a and V2 arginine vasopressin receptors. Regul. Pept. 1993, 45:53-59.
63. Murgatroyd C., Wigger A., Frank E., Singewald N., Bunck M., Holsboer F., Landgraf R., Spengler D. Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J. Neurosci. 2004, 24:7762-7770.
64. Neumann I.D., Veenema A.H., Beiderbeck D.I. Aggression and anxiety: social context and neurobiological links. Front. Behav. Neurosci. 2010, 4:12.
65. Nishimura H., Tsuda A., Ida Y., Tanaka M. The modified forced-swim test in rats: influence of rope- or straw-suspension on climbing behavior. Physiol. Behav. 1988, 43:665-668.
66. Overstreet D.H., Griebel G. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol. Biochem. Behav. 2005, 82:223-227.
67. Pellegrino K.J., Pellegrino A.S., Cushman A.J. An Atereotaxic Atlas of the Brain 1979, Plenum, New York.
68. Plotsky P.M., Owens M.J., Nemeroff C.B. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr. Clin. North Am. 1998, 21:293-307.
69. Purba J.S., Hoogendijk W.J., Hofman M.A., Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 1996, 53:137-143.
70. Rabadan-Diehl C., Lolait S.J., Aguilera G. Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat. J. Neuroendocrinol. 1995, 7:903-910.
71. Ramos A.T., Troncone L.R., Tufik S. Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stressmodels. Neuroendocrinology 2006, 84:309-316.
72. Raskind M., Orenstein H., Weitzman R.E. Vasopressin in depression. Lancet 1979, 1:164.
73. Ring R.H. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Des. 2005, 11:205-225.
74. Rivier C., Rivier J., Mormede P., Vale W. Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat. Endocrinology 1984, 115:882-886.
75. Saito M., Sugimoto T., Tahara A., Kawashima H. Molecular cloning and characterization of rat V1b vasopressin receptor: evidence for its expression in extra-pituitary tissues. Biochem. Biophys. Res. Commun. 1995, 212:751-757.
76. Salomé N., Stemmelin J., Cohen C., Griebel G. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) 2006, 187:237-244.
77. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Pinto E., Reggers J., Ansseau M., Legros J.J. AVP- and OT-neurophysins response to apomorphine and clonidine in major depression. Psychoneuroendocrinology 2005, 30:839-845.
78. Schelling P., Meyer D., Loos H.E., Speck G., Phillips M.I., Johnson A.K., Ganten D. A micromethod for measurement of rennin in brain nuclei: its application in spontaneously hypertensive rats. Meuropharmacology 1982, 21:455-463.
79. Serradeil-Le Gal C., Wagnon J., Simiand J., Griebel G., Lacour C., Guillon G., Barberis C., Brossard G., Soubrie P., Nisato D. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phe-nyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrro-lidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther. 2002, 300:1122-1130.
80. Serradeil-Le Gal C., Wagnon J., Tonnerre B., Roux R., Garcia G., Griebel G., Aulombard A. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev. 2005, 11:53-68.
81. Shimazaki T., Iijima M., Chaki S. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats. Eur. J. Pharmacol. 2006, 543:63-67.
82. Simon N.G., Guillon C., Fabio K., Heindel N.D., Lu S.F., Miller M., Ferris C.F., Brownstein M.J., Garripa C., Koppel G.A. Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Pat CNS Drug Discov. 2008, 3:77-93.
83. Surget A., Belzung C. Involvement of vasopressin in affective disorders. Eur. J. Pharmacol. 2008, 583:340-349.
84. Tendis S., Klingberg F., Schaeker W. Arginine-vasopressin and lysine-vasopressin have different effects on spontaneous behaviour of rats. Biomed. Biochim. Acta 1987, 46:719-725.
85. Thibonnier M. Signal transduction of V1-vascular vasopressin receptors. Regul. Pept. 1992, 38:1-11.
86. Thompson R., Gupta S., Miller K., Mills S., Orr S. The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology 2004, 29:35-48.
87. Varga J., Domokos A., Barna I., Jankord R., Bagdy G., Zelena D. Lack of vasopressin does not prevent the behavioural and endocrine changes induced by chronic unpredictable stress. Brain Res. Bull. 2011, 84:45-52.
88. Watson S., Gallagher P., Ferrier I.N., Young A.H. Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. J. Psychiatr. Res. 2006, 40:353-359.
89. Wersinger S.R., Caldwell H.K., Christiansen M., Young W.S. Disruption of the vasopressin 1b receptor gene impairs the attack component of social behavior in mice. Genes Brain Behav. 2006, 6:653-660.
90. Wersinger S.R., Caldwell H.K., Martinez L., Gold P., Hu S.B., Young W.S. Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav. 2007, 6:540-551.
91. Wersinger S.R., Ginns E.I., O'Carroll A.M., Lolait S.J., Young W.S. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol. Psychiatry 2002, 7:975-984.
92. Wersinger S.R., Kelliher K.R., Zufall F., Lolait S.J., O'Carroll A., Young W.S.I.I.I. Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm. Behav. 2004, 46:638-645.
93. Wigger A., Sánchez M.M., Mathys K.C., Ebner K., Frank E., Liu D., Kresse A., Neumann I.D., Holsboer F., Plotsky P.M., Landgraf R. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology 2004, 29:1-14.
94. Willcox B.J., Poulin P., Veale W.L., Pittman Q.J. Vasopressin-induced motor effects: localization of a sensitive site in the amygdala. Brain Res. 1992, 596:58-64.
95. de Winter R.F., van Hemert A.M., Derijk R.H., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., Wiegant V.M., Goekoop J.G. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003, 28:140-147.
96. Yan H.C., Cao X., Das M., Zhu X.H., Gao T.M. Behavioral animal models of depression. Neurosci. Bull. 2010, 26:327-337.
97. Yang J., Song C.Y., Liu W.Y., Lin B.C. Only through the brain nuclei, arginine vasopressin regulates antinociception in the rat. Peptides 2006, 27:3341-3346.
98. Yang J., Yuan H.F., Chu J.G., Yang Y., Xu H.T., Wang G., Liu W.Y., Lin B.C. Arginine vasopressin antinociception in the rat nucleus raphe magnus is involved in the endogenous opiate peptide and serotonin system. Peptides 2009, 30:1355-1361.
99. Young L.J. Oxytocin and vasopressin receptors and species-typical social behaviors. Horm. Behav. 1999, 36:212-221.